Brokerages Set WAVE Life Sciences Ltd. (NASDAQ:WVE) Target Price at $22.53

Posted by Brenda Bartman on Aug 17th, 2026

Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE – Get Free Report) have been given a consensus rating of “Moderate Buy” by the sixteen research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, fourteen have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $22.5294.

A number of research analysts recently weighed in on WVE shares. Truist Financial started coverage on shares of WAVE Life Sciences in a report on Wednesday, April 29th. They issued a “buy” rating and a $15.00 price objective for the company. UBS Group set a $13.00 target price on shares of WAVE Life Sciences in a report on Monday, August 3rd. Wedbush decreased their price target on shares of WAVE Life Sciences from $15.00 to $12.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. B. Riley Financial dropped their price target on shares of WAVE Life Sciences from $31.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Finally, Mizuho cut their price objective on WAVE Life Sciences from $27.00 to $23.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 4th.

Read Our Latest Stock Analysis on WVE

Insiders Place Their Bets

In other WAVE Life Sciences news, Director Heidi L. Wagner sold 7,000 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $6.01, for a total transaction of $42,070.00. Following the sale, the director owned 44,930 shares in the company, valued at $270,029.30. This represents a 13.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Adrian Rawcliffe sold 12,700 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $5.29, for a total value of $67,183.00. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 23,564 shares of company stock valued at $132,476. 24.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On WAVE Life Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in WVE. Handelsbanken Fonder AB increased its stake in shares of WAVE Life Sciences by 25.0% during the second quarter. Handelsbanken Fonder AB now owns 81,900 shares of the company’s stock worth $476,000 after buying an additional 16,400 shares during the period. Bank of America Corp DE lifted its stake in WAVE Life Sciences by 29.5% in the first quarter. Bank of America Corp DE now owns 236,760 shares of the company’s stock worth $1,717,000 after acquiring an additional 53,905 shares during the last quarter. ADAR1 Capital Management LLC purchased a new position in WAVE Life Sciences in the first quarter worth approximately $326,000. California State Teachers Retirement System lifted its stake in WAVE Life Sciences by 34.8% in the first quarter. California State Teachers Retirement System now owns 145,206 shares of the company’s stock worth $1,053,000 after acquiring an additional 37,526 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in WAVE Life Sciences by 31.9% during the 1st quarter. The Manufacturers Life Insurance Company now owns 240,983 shares of the company’s stock worth $1,747,000 after acquiring an additional 58,255 shares in the last quarter. 89.73% of the stock is owned by institutional investors and hedge funds.

WAVE Life Sciences Price Performance

Shares of WAVE Life Sciences stock opened at $5.41 on Monday. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of -4.96 and a beta of -1.26. The business has a 50-day moving average of $5.88 and a 200 day moving average of $8.37. WAVE Life Sciences has a 12 month low of $5.01 and a 12 month high of $21.73.

WAVE Life Sciences (NASDAQ:WVE – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04). The business had revenue of $2.27 million for the quarter, compared to analysts’ expectations of $7.45 million. WAVE Life Sciences had a negative return on equity of 50.36% and a negative net margin of 309.73%. Equities research analysts anticipate that WAVE Life Sciences will post -1.11 earnings per share for the current year.

About WAVE Life Sciences

(Get Free Report)

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.